Sugi Predict

Sugi Predict / Compounds / SCHEMBL16513631

SCHEMBL16513631

SCHEMBL16513631

c1ccc(-c2cccc3cnc(Nc4ccc(N5CCOCC5)cc4)nc23)cc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK10 P53779 7/20 0.79
▸ JUN P05412 6/20 0.79
▸ MAPK8 P45983 5/20 0.79
▸ TTK P33981 1/20 0.69
▸ JAK2 O60674 2/20 0.60
▸ IGF1R P08069 1/20 0.58
▸ STAT6 P42226 1/20 0.58
▸ BRD4 O60885 1/20 0.56
▸ PLK4 O00444 1/20 0.56
▸ INSR P06213 1/20 0.55
▸ CDK1 P06493 2/20 0.55
▸ CDK4 P11802 2/20 0.55
▸ CCNB1 P14635 2/20 0.55
▸ CCND1 P24385 2/20 0.55
▸ CCNE1 P24864 2/20 0.55
▸ CDK2 P24941 2/20 0.55
▸ SYK P43405 1/20 0.54
▸ FGFR2 P21802 1/20 0.54
▸ PTK2 Q05397 1/20 0.53
▸ EGFR P00533 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29847439 1.00 MAPK10 (0.79) MAPK10JUNMAPK8TTKJAK2
SCHEMBL16513865 0.89 MAPK10 (0.64) MAPK10JUNMAPK8TTKJAK2
SCHEMBL16513490 0.89 MAPK10 (0.64) MAPK10JUNMAPK8TTKJAK2
SCHEMBL16514799 0.89 JAK2 (0.66) MAPK10JUNMAPK8TTKJAK2
SCHEMBL16514447 0.88 MAPK10 (0.66) MAPK10JUNMAPK8TTKJAK2
SCHEMBL29848408 0.88 MAPK10 (0.66) MAPK10JUNMAPK8TTKJAK2
SCHEMBL16513553 0.88 JUN (0.66) MAPK10JUNMAPK8TTKJAK2
SCHEMBL18376760 0.88 TTK (0.66) MAPK10JUNMAPK8TTKJAK2
SCHEMBL16514379 0.87 JUN (0.62) MAPK10JUNMAPK8TTKIGF1R
SCHEMBL16513597 0.87 JUN (0.62) MAPK10JUNMAPK8TTKIGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105682661-B Certain chemical entities, compositions, and methods 润新生物公司 2020-03-27 — — CN claimed
CN-109851617-A Chemical entities, composition and method 润新生物公司 2019-06-07 — — CN claimed
US-9849139-B2 Substituted quinazolines for inhibiting kinase activity NEUPHARMA, INC. (US) 2017-12-26 — — US claimed
US-20170196881-A1 SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY NEUPHARMA, INC. 2017-07-13 — — US claimed
US-9550770-B2 Substituted quinazolines for inhibiting kinase activity NEUPHARMA, INC. (US) 2017-01-24 — — US claimed
EP-3035936-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NeuPharma, Inc. (US) 2016-06-29 — — EP claimed
CN-105682661-A Certain chemical entities, compositions, and methods 润新生物公司 2016-06-15 — — CN claimed
US-20150175601-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. 2015-06-25 — — US claimed
WO-2015027222-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. (US) 2015-02-26 — — WO claimed
US-20260102406-A1 SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY NEUPHARMA INC (US) 2026-04-16 — — US disclosed
EP-3508204-B1 QUINAZOLIN-8-YL DERIVATIVES FOR USE IN METHODS OF TREATING MELANOMA, NON-SMALL CELL LUNG CANCER, THYROID CANCER, OVARIAN CANCER, OR COLON CANCER NEUPHARMA INC (US) 2026-02-11 — — EP disclosed
US-12403145-B2 Substituted quinazolines for inhibiting kinase activity NEUPHARMA, INC (US) 2025-09-02 — — US disclosed
US-20240197752-A1 SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY NEUPHARMA INC 2024-06-20 — — US disclosed
US-11865120-B2 Substituted quinazolines for inhibiting kinase activity NEUPHARMA, INC. (US) 2024-01-09 — — US disclosed
CN-105682661-A Certain chemical entities, compositions, and methods 润新生物公司 2016-06-15 — — CN disclosed
US-20150175601-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. 2015-06-25 — — US disclosed
US-20150175601-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. 2015-06-25 — — US disclosed
US-20150175601-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. 2015-06-25 — — US disclosed
WO-2015027222-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. (US) 2015-02-26 — — WO disclosed
WO-2015027222-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. (US) 2015-02-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170196881-A1 SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY DCK, ABL1, MAP4K2 MAPK10 347/4885JUN 1830/4885MAPK8 212/4885
US-20240197752-A1 SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY DCK, ABL1, MAP4K2 MAPK10 347/4885JUN 1830/4885MAPK8 212/4885
US-11865120-B2 Substituted quinazolines for inhibiting kinase activity DCK, ABL1, MAP4K2 MAPK10 347/4885JUN 1830/4885MAPK8 212/4885
US-20150175601-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS BRAF, PIK3CA, PLK1 MAPK10 395/4885JUN 3073/4885MAPK8 246/4885
US-12403145-B2 Substituted quinazolines for inhibiting kinase activity DCK, ABL1, MAP4K2 MAPK10 347/4885JUN 1830/4885MAPK8 212/4885
US-20260102406-A1 SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY BRAF, TTK, MAP4K2 MAPK10 220/4885JUN 1577/4885MAPK8 65/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.